A gene expression profile indicative of early stage HER2 targeted therapy response

BACKGROUND: Efficacious application of HER2-targetting agents requires the identification of novel predictive biomarkers. Lapatinib, afatinib and neratinib are tyrosine kinase inhibitors (TKIs) of HER2 and EGFR growth factor receptors. A panel of breast cancer cell lines was treated with these agent...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Neill, Fiona, Madden, Stephen F, Clynes, Martin, Crown, John, Doolan, Padraig, Aherne, Sinéad T, O’Connor, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725168/
https://www.ncbi.nlm.nih.gov/pubmed/23816254
http://dx.doi.org/10.1186/1476-4598-12-69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725168/
https://www.ncbi.nlm.nih.gov/pubmed/23816254
http://dx.doi.org/10.1186/1476-4598-12-69

Ejemplares similares